History of Quincy Bioscience
Quincy Bioscience is a biotechnology company with its primary consumer product called Prevagen®, a dietary supplement designed to support brain health and to improve cognitive function. Currently Prevagen is the No. 1 selling brain health supplement per Nielsen data (December, 2015) in chain pharmacies in the United States including distribution in Walgreens, Rite Aid and CVS stores in addition to placement in several thousand independent health food stores and pharmacies.
The main focus of Quincy is the discovery, development and commercialization of novel technologies to support cognitive function and other normal health challenges associated with aging. Clinical data on Prevagen has demonstrated a strong relationship with improvements in quantitative measures on cognitive function, specifically verbal learning1 in a double-blind and placebo-controlled human clinical trials. This trial and other research on apoaequorin have been published in peer-reviewed journals and presented at various international neuroscience conferences.
Quincy Bioscience’s first headquarters building was located in the University Research Park in Madison, Wisconsin, in the fall of 2004. Simultaneously, a partnership was formed with the laboratory of Dr. James R. Moyer, Jr. of the University of Wisconsin at Milwaukee. Dr. Moyer is a leading expert in the field of memory and cognitive function.
To accommodate growth in all areas of the organization, Quincy Bioscience moved out of the University Research Park in 2010 and then again to its current location in 2015, to accommodate growing staff and future needs.
In 2014, a regional office was established in Dallas, Texas.
1. Marone, P.A., Bauter, M., Hofman-Hüther, H., and Moran, D. (2013). Safety assessment of Apoaequorin preparation: Subchronic toxicity study in rats. Food and Chemical Toxicology 57. Research was conducted by Eurofins/Product Safety Labs under the advisement of Soni and Associates, Inc. Funding provided by Quincy Bioscience.
Marone, P.A., Bauter, M., Hofman-Hüther, H., and Moran, D. (2013). Toxicologic Evaluation of Apoaequorin. Poster presented at the Society of Toxicology Annual Meeting, San Antonio, Texas. Research was conducted by Eurofins/Product Safety Labs under the advisement of Soni and Associates, Inc. Funding provided by Quincy Bioscience.